Zahraa K Lawi1, Mohammed Baqur S Al-Shuhaib2, Ibtissem Ben Amara3. 1. Department of Biology, College of Science, University of Kufa, Najaf, 54001, Iraq. 2. Department of Animal Production, College of Agriculture, Al-Qasim Green University, Al-Qasim-8, Babil, 51001, Iraq. mohammed79@agre.uoqasim.edu.iq. 3. Higher Institute of Biotechnology of Sfax, Sfax University, Sfax, 3000, Tunisia.
Abstract
PURPOSE: N-acetyltransferase 2 is an enzyme that is involved in the detoxification of carcinogens in the human body, so any damage to this protein may lead to the emergence of several metabolic dysfunctions. This work was conducted to determine the association between NAT2 polymorphism and non-small cell lung carcinoma (NSCLC) that is increasingly reported in the Iraqi population. METHODS: PCR sequencing was conducted to assess the possible association between genetic variants and NSCLC. Several in silico tools were implemented to investigate the effect of the observed SNPs on the structure, function, and stability of the altered NAT2. RESULTS: Five SNPS of NAT2 (rs1208, rs1041983, rs1799929, rs1799930, and rs1801280) were identified in high frequencies in the amplified fragment. These SNPs showed variable distributions of haplotypes between cases and controls. No significant association of rs1208, rs1041983, rs1799929, and rs1799930 with NSCLC was shown in the investigated population. In contrast, rs1801280: CC genotype showed a highly significant (P = 0.009) association with the NSCLC, and individuals with this genotype had 2.19 more chances for developing NSCLC (OR 2.19; Cl95% 1.21-3.94). Association analysis of rs1801280 SNP distribution among the investigated patients showed that patients with CC genotype showed a significant (P = 0.02, OR 2.65) association with family history, which entailed a high hereditary possibility of this genotype among Iraqi patients. It was predicted that this SNP showed high damaging effects on the activity of NAT2 enzyme, with various deleterious outcomes on enzyme structure, function, and stability. CONCLUSION: Data indicated that rs1801280 SNP exerted a tight association with NSCLC since individuals with CC genotype exhibited the most damaging effects on the NAT2 that may be behind the low acetylation rates of this enzyme in patients with NSCLC.
PURPOSE: N-acetyltransferase 2 is an enzyme that is involved in the detoxification of carcinogens in the human body, so any damage to this protein may lead to the emergence of several metabolic dysfunctions. This work was conducted to determine the association between NAT2 polymorphism and non-small cell lung carcinoma (NSCLC) that is increasingly reported in the Iraqi population. METHODS: PCR sequencing was conducted to assess the possible association between genetic variants and NSCLC. Several in silico tools were implemented to investigate the effect of the observed SNPs on the structure, function, and stability of the altered NAT2. RESULTS: Five SNPS of NAT2 (rs1208, rs1041983, rs1799929, rs1799930, and rs1801280) were identified in high frequencies in the amplified fragment. These SNPs showed variable distributions of haplotypes between cases and controls. No significant association of rs1208, rs1041983, rs1799929, and rs1799930 with NSCLC was shown in the investigated population. In contrast, rs1801280: CC genotype showed a highly significant (P = 0.009) association with the NSCLC, and individuals with this genotype had 2.19 more chances for developing NSCLC (OR 2.19; Cl95% 1.21-3.94). Association analysis of rs1801280 SNP distribution among the investigated patients showed that patients with CC genotype showed a significant (P = 0.02, OR 2.65) association with family history, which entailed a high hereditary possibility of this genotype among Iraqi patients. It was predicted that this SNP showed high damaging effects on the activity of NAT2 enzyme, with various deleterious outcomes on enzyme structure, function, and stability. CONCLUSION: Data indicated that rs1801280 SNP exerted a tight association with NSCLC since individuals with CC genotype exhibited the most damaging effects on the NAT2 that may be behind the low acetylation rates of this enzyme in patients with NSCLC.
Authors: Marianne Rodrigues Fernandes; Darlen Cardoso de Carvalho; Ândrea Kelly Campos Ribeiro dos Santos; Sidney Emanuel Batista dos Santos; Paulo Pimentel de Assumpção; Rommel Mario Rodriguez Burbano; Ney Pereira Carneiro dos Santos Journal: Anticancer Res Date: 2013-09 Impact factor: 2.480
Authors: Heidi A Hamann; Elizabeth S Ver Hoeve; Lisa Carter-Harris; Jamie L Studts; Jamie S Ostroff Journal: J Thorac Oncol Date: 2018-05-23 Impact factor: 15.609
Authors: Angel Diaz-Lagares; Jesus Mendez-Gonzalez; David Hervas; Maria Saigi; Maria J Pajares; Diana Garcia; Ana B Crujerias; Ruben Pio; Luis M Montuenga; Javier Zulueta; Ernest Nadal; Antoni Rosell; Manel Esteller; Juan Sandoval Journal: Clin Cancer Res Date: 2016-02-03 Impact factor: 12.531